Oxypurinol Compared With Placebo for Class III-IV NYHA Congestive Heart Failure
Status:
Completed
Trial end date:
2005-06-01
Target enrollment:
Participant gender:
Summary
The OPT-CHF (OxyPurinol Therapy for CHF) study is designed to demonstrate the efficacy and
safety of oral oxypurinol vs. placebo in a randomized, double-blind, twenty-four week trial
in 400 patients in up to 50 centers. Measures of clinical efficacy (NYHA class and Patient
Global Assessment) as well as clinical outcomes (e.g., death, worsening heart failure, and
hospitalization) will be assessed as a composite endpoint in this trial.